Telemedicine Prescribing in 2026: What’s Actually in Effect Right Now
You can still prescribe Schedule II-V controlled substances via telemedicine without an in-person exam. That ends December 31, 2026 — unless the DEA acts first. This is the Fourth Temporary Extension, not a permanent fix.
What’s Actually in Effect Right Now?
Three separate rules govern telemedicine prescribing today. They don’t expire on the same schedule.
The Fourth Temporary Extension (90 FR 61301) covers the broadest flexibility. Any DEA-registered practitioner can prescribe Schedule II-V controlled substances via real-time audio-video telemedicine. No prior in-person exam required. It took effect January 1, 2026, and runs through December 31, 2026.
Two permanent rules sit alongside it. The buprenorphine telemedicine rule (90 FR 6504) and the VA continuity-of-care rule (90 FR 6523) both got finalized in January 2025. A regulatory freeze delayed both twice before they finally took effect December 31, 2025. They’re permanent. They don’t expire.
What About the Special Registration Rule Everyone’s Waiting For?
It’s still just a proposal. DEA published the Special Registration for Telemedicine framework back in January 2025. As of mid-2026 it remains unfinalized. No confirmed effective date exists.
Don’t build your compliance plan around it. It might look nothing like the current draft by the time it’s final — if it finalizes at all.
Why You Shouldn’t Wait Until December
If the extension expires without a replacement, every patient you’ve never seen in person loses telemedicine access to controlled substance prescriptions from you. Wait until Q4 2026 to convert those patients and you’re competing with every other practice for the same appointment slots.
How to Get Ahead of It
Start with your own patient list, not the regulatory calendar.
- Pull every patient currently receiving controlled substances through telemedicine and flag who’s never had an in-person visit with you.
- Sort that list by clinical urgency. Patients who genuinely need in-person evaluation go first.
- Build referral relationships now for patients too far away to see you in person.
- Add a discrete “in-person status” field to your EMR so you can prove compliance instantly if asked.
- Consult your compliance counsel.
Source
Federal Register — Expansion of Buprenorphine Treatment via Telemedicine Encounter (90 FR 6504)
Federal Register — Continuity of Care via Telemedicine for Veterans Affairs Patients (90 FR 6523)
This post is for educational purposes only and does not constitute legal or compliance advice. Consult a qualified attorney or compliance professional before acting on this information.
